Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia

American Journal of Health-System Pharmacy

Volumn 54, Issue 10, 1997, Pages 1180-1184

  Huse, Daniel M ^a   Schainbaum, Sandra ^b   Kirsch, Arlene J ^b   Tyring, Stephen ^c  

^a Medical Research International   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Age; Antivirals; Costs; Decision making; Economics; Famciclovir; Herpes zoster; Models; Neuralgia

Indexed keywords

ACICLOVIR; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CAPSAICIN; CARBAMAZEPINE; CODEINE PHOSPHATE; CORTICOSTEROID; FAMCICLOVIR; NARCOTIC ANALGESIC AGENT; PARACETAMOL; PREDNISONE; VALACICLOVIR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG COST; ECONOMIC EVALUATION; HEADACHE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HERPES ZOSTER; HUMAN; MODEL; MULTICENTER STUDY; NERVE BLOCK; ORAL DRUG ADMINISTRATION; PHYSIOTHERAPY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; TRANSCUTANEOUS NERVE STIMULATION;

EID: 0030904668     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.10.1180     Document Type: Article

References (19)

1. Gnann JW, Whitley RJ. Natural history and treatment of varicella-zoster in high-risk populations. J Hosp Infect. 1991; 18(suppl A):317-29.
2. Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: clinical review and current management. Ann Neurol. 1986; 20:651-64.
3. Gilden DH. Herpes zoster with postherpetic neuralgia - persisting pain and frustration. N Engl J Med. 1994; 330:932-4.
4. Hope-Simpson RE. Herpes zoster in general practice: post herpetic neuralgia. J R Coll Gen Pract. 1975; 25:571-5.
5. Ragozzino MW, Melton LJ, Kurland LT et al. Population-based study of herpes zoster and its sequelae. Medicine. 1982; 61:310-6.
6. Davies L, Cossins L, Bowsher D et al. The cost of treatment for post-herpetic neuralgia in the UK. Pharmacoeconomics. 1994; 6:142-8.
7. Tyring S, Nahlik JE, Cunningham A et al. A double-blind, randomized, placebo-controlled, parallel group study of oral famciclovir for the treatment of uncomplicated herpes zoster. Ann Intern Med. 1995; 123:89-96.
8. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA. 1989; 262:2879-86.
9. Lis Y, Mann RD. The VAMP research multi-purpose database in the U.K. J Clin Epidemiol. 1995; 48:431-43.
10. Wholesale price list. Philadelphia: SmithKline Beecham Pharmaceuticals; 1996.
11. Schafermeyer KW, Schondelmeyer SW, Thomas J et al. An analysis of the cost of dispensing third-party prescriptions in chain pharmacies. J Res Pharm Econ. 1992; 4(3):3-24.
12. Physicians' desk reference. 50th ed. Montvale, NJ: Medical Economics; 1996.
13. Saltzman R, Boon R. The safety of famciclovir in patients with herpes zoster. Curr Ther Res. 1995; 56:219-25.
14. Red book. Doherty MC, ed. Montvale, NJ: Medical Economics; 1995.
15. Health Care Financing Administration. Medicare program; refinements to geographic adjustment factor values, revisions to payment policies, adjustments to the relative value units (RVUs) under the physician fee schedule for calendar year 1995, and the 5-year refinement of RVUs. Fed Regist. 1994; 59:63410-635.
16. Burgoon CF, Burgoon JS, Baldridge GD. The natural history of herpes zoster. JAMA. 1957; 164:265-9.
17. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Australia: Australian Government Publishing Service; 1992.
18. Clemens K, Townsend R, Luscombe F et al. Methodological and conduct principles for pharmacoeconomic research. Pharmacoeconomics. 1995; 8:169-74.
19. Whitley RJ, Gnann JW. Acyclovir: a decade later. N Engl J Med. 1992; 327:782-9.